PIK3CA and colorectal cancer: Moreover, although limited experimental data are available to explore the exact prognostic value of PIK3CA mutations on the efficacy of cetuximab in NSCLC, activating PIK3CA mutations in only the p110α catalytic domain, and not in the helical domain, appear to grant similar resistance to cetuximab in colorectal cancer cohorts (Table 1) [77].